SPARTANBURG, S.C., Aug. 16, 2011 /PRNewswire/ — Femasys Inc.
and Norgenix Pharmaceuticals, LLC today announced an agreement for
exclusive distribution rights in the United States as well as US
territories and military bases for Femasys’ FemVue™
Saline-Air Device. This FDA cleared device is used to evaluate a
woman’s fallopian tubes with standard ultrasound, called a Sono
HSG. Femasys Inc. is an emerging medical device developer of
women’s healthcare solutions. Norgenix Pharmaceuticals, LLC, a
wholly owned subsidiary of the J M Smith Corporation, is a North
American distributor with a world-class sales channel for medical
device and pharmaceutical products in the women’s health arena.
Norgenix is licensed to sell, market, and distribute medical
devices and prescription drug products in all 50 US states.
“Our agreement with Norgenix is anticipated to have an immediate
and significant impact on our sales expansion efforts as we offer
the market an advancement in diagnostic care for an infertile
woman,” stated Kathy Lee-Sepsick, President & CEO of Femasys
Inc. “The Norgenix team is providing us with multiple ready-made
relationships; we are excited to ramp our production to meet the
numerous opportunities Norgenix has presented.”
The FemVue™ Saline-Air Device has been cleared by the FDA
for use during diagnostic Sono HSG for fallopian tube evaluations.
It creates a consistent alternating pattern of saline and air used
as contrast allowing physicians to evaluate a woman’s fallopian
tubes with existing ultrasound equipment. With the FemVue pattern
of saline and air, Sono HSG can be a reliable, cost-effective,
convenient, and safe procedure performed quickly by a woman’s
gynecologist or infertility specialist in the office.
“We are pleased to announce our partnership with Femasys,”
stated Ken Couch, President of Norgenix Pharmaceuticals, LLC.
“Femasys’ FemVue device is an innovative product that perfectly
aligns with our strategic
‘/>”/>
